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Signaling mechanisms underlying self-renewal of
leukemic stem cells (LSCs) are poorly understood,
and identifying pathways specifically active in LSCs
could provide opportunities for therapeutic inter-
vention. T-cell immunoglobin mucin-3 (TIM-3) is ex-
pressed on the surface of LSCs in many types of
human acute myeloid leukemia (AML), but not on he-
matopoietic stem cells (HSCs). Here, we show that
TIM-3 and its ligand, galectin-9 (Gal-9), constitute
an autocrine loop critical for LSC self-renewal and
development of human AML. Serum Gal-9 levels
were significantly elevated in AML patients and in
mice xenografted with primary human AML samples,
and neutralization of Gal-9 inhibited xenogeneic
reconstitution of human AML. Gal-9-mediated stimu-
lation of TIM-3 co-activated NF-kB and b-catenin
signaling, pathways known to promote LSC self-
renewal. These changes were further associated
with leukemic transformation of a variety of pre-
leukemic disorders and together highlight that tar-
geting the TIM-3/Gal-9 autocrine loop could be a
useful strategy for treating myeloid leukemias.
INTRODUCTION
Acute myeloid leukemia (AML) originates from self-renewing
leukemic stem cells (LSCs), and purified human LSCs can repo-
pulate human AML in immunodeficient mice after xenogeneic
transplantation (Bonnet and Dick, 1997). In humans, AML LSCs
are highly concentrated in the CD34+CD38 fraction whose
phenotype is analogous to normal hematopoietic stem cells
(HSCs), but AML LSCs also have granulocyte/monocyte progen-
itor (GMP)-like phenotype that are CD45RA+CD123+ (Yoshimoto
et al., 2009). In mouse AML models, LSCs can arise from HSCs
as well as from GMPs after introduction of AML-related chimeric
fusion genes (Cozzio et al., 2003; Huntly et al., 2004; Krivtsov
et al., 2006). LSCs should be an ultimate target for eradicationCell Sof human AML. Previous studies have reported a number of sur-
face molecules expressed in AML LSCs but not in normal HSCs,
including CLL-1 (van Rhenen et al., 2007), CD25 (Saito et al.,
2010), CD32 (Saito et al., 2010), and CD96 (Hosen et al., 2007).
Recently, we and others have reported that the T-cell immuno-
globulin mucin-3 (TIM-3) is expressed on the surface of LSCs
in all types of AML by French-American-British (FAB) classifica-
tion with only exception of M3 (acute promyelocytic leukemia
[APL]) (Jan et al., 2011; Kikushige et al., 2010). Because TIM-3
is not expressed in normal human HSCs and because only
TIM-3+ but not TIM-3 fraction of human AML cells can reconsti-
tute human AML in immunodeficient mice (Jan et al., 2011; Ki-
kushige et al., 2010), surface TIM-3 should be a strong candidate
for therapeutic target. In fact, cytotoxic anti-human TIM-3 anti-
bodies could eradicate human AML LSCs in immunodeficient
mice without affecting normal hematopoiesis (Kikushige et al.,
2010), suggesting that targeting TIM-3 should be a very prom-
ising therapeutic approach for human AML.
TIM-3 is a type 1 cell-surface glycoprotein and was identified
originally as a surface molecule expressed in CD4+ Th1 cells
in mice (Monney et al., 2002). In human, it is expressed also in a
fraction of T cells, NK cells, monocytes, and dendritic cells
(DCs) (Anderson et al., 2007; DeKruyff et al., 2010; Gleason
et al., 2012; Ndhlovu et al., 2012). Galectin-9 (Gal-9), a ligand of
TIM-3, is a b-galactoside binding lectin that contains two
carbohydrate recognition domains (CRDs) (Wada and Kanwar,
1997) and binds to N-terminal immunoglobulin variable (IgV)
domain of TIM-3 through its two CRDs (Zhu et al., 2005). The
function of TIM-3 by Gal-9 ligation has been investigated largely
in mouse hematopoiesis. Ligation of TIM-3 by Gal-9 has been
shown to phosphorylate tyrosine residues of the cytoplasmic
tail of TIM-3 and activate Src family kinases through its Src ho-
mology 2 (SH2) bindingmotif in T cells andmonocytes (Anderson
et al., 2007; Lee et al., 2011; van de Weyer et al., 2006). TIM-3
signaling induced by Gal-9 ligation exerts pleiotropic effects in
immune cells. It induces apoptosis in Th1 cells and negatively
regulates the Th1 cell functions (Zhu et al., 2005), whereas in
monocytes, its signaling stimulates secretion of tumor necrosis
factor-a (TNF-a) and its maturation into DCs (Nagahara et al.,
2008), eventually promoting inflammation by innate immunity
(Anderson et al., 2007; Kuchroo et al., 2008). It is, however, un-
known whether TIM-3 expression in human AML LSCs merelytem Cell 17, 341–352, September 3, 2015 ª2015 Elsevier Inc. 341
reflects activation of monocyte-related genes in AML (Kikushige
et al., 2010) or whether TIM-3 signaling has a specific function.
Here, we demonstrate evidence that human AML cells secrete
a high amount of Gal-9 into patients’ sera and that ligation of
TIM-3 by Gal-9 activates both NF-kB and b-catenin pathways,
presumably to stimulate self-renewal (Schwitalla et al., 2013)
of LSCs. Neutralization of human Gal-9 significantly inhibited
reconstitution of human AML in immunodeficient mice. Further-
more, upregulation of TIM-3, production of Gal-9, and activation
of NF-kB and b-catenin signaling by TIM-3 ligation were always
associated not only with primary AML, but also with leukemic
transformation from a variety of preleukemic diseases, such as
myelodysplastic syndromes (MDSs) and myeloproliferative neo-
plasms (MPNs), including chronic myelogenous leukemia (CML).
Our data suggest that TIM-3 and Gal-9 constitute an essential
autocrine stimulatory loop for LSCs to outgrow normal HSCs,
presumably representing a universal machinery for development
and maintenance of human myeloid malignant stem cells.RESULTS
Human Gal-9 Is a Ligand for TIM-3 in Primary Human
AML Cells
We verified that humanGal-9 binds to the extracellular domain of
human TIM-3. To measure the binding activity between human
TIM-3 and human Gal-9 proteins, we performed a surface plas-
mon resonance (SPR) assay by using the Biacore T100 system
(GEHealthcare). Human TIM-3-FLAG-Fc proteins were captured
on a sensor chip via anti-human IgG antibodies, and then either
human recombinant Gal-1, Gal-9, or control buffer was injected
to measure changes in the resonance unit. As shown in Fig-
ure 1A, Gal-9, but not Gal-1, showed a response against human
TIM-3-FLAG-Fc proteins, indicating that Gal-9 physiologically
binds to the extracellular domain of human TIM-3.
The clinical characteristics of AML patients analyzed in this
study are summarized in Table S1. In 32 of 35 patients, the
vast majority of AML LSCs expressed TIM-3 (TIM-3+ AML),
whereas the remaining 3 patients, including 1 APL, did not
(TIM-3 AML). We purified the CD34+ AML cells from 5 TIM-3+
AML patients and performed immunoprecipitation-western blot
(IP-WB) analysis for human Gal-9. Gal-9 was immunoprecipi-
tated together with TIM-3 in all cases tested, demonstrating
that Gal-9 physiologically binds to TIM-3 in primary AML cells
(Figure 1B). Thus, Gal-9 should be a ligand for TIM-3 in human
as in case of mouse (Zhu et al., 2005).Primary Human TIM-3+ AML Cells Secrete Gal-9 into the
Serum at a High Level
Since primary AML cells had Gal-9 bound to surface TIM-3,
we evaluated serum concentration of Gal-9 in TIM-3+ AML
patients by an ELISA (Figure 1C). Strikingly, the serum Gal-9
was significantly elevated in 15 AML patients tested. Mean
levels of serum Gal-9 were 391.8 pg/ml in AML (n = 15),
whereas they were 22.4, 33.5, and 32.3 pg/ml in healthy indi-
viduals (n = 12), patients with non-Hodgkin lymphoma (n = 5),
and patients with B cell type acute lymphoblastic leukemia (B-
ALL) (n = 8), respectively. These data suggest that AML cells
themselves secrete Gal-9.342 Cell Stem Cell 17, 341–352, September 3, 2015 ª2015 Elsevier IIt has been shown that Gal-9 is expressed in various tissues
involved in the immune system, including spleen, thymus, and
lymphocytes, and in tissues of endodermal origin such as liver,
intestine, and lung (Heusschen et al., 2013). Interestingly, both
AML LSC (CD34+CD38) and primitive blast (CD34+CD38+)
populations had a high level of intracytoplasmic Gal-9 in all eight
AML patients tested (Figure 1D). In normal hematopoiesis, HSCs
and hematopoietic progenitor cells (HPCs) had Gal-9 at a similar
level (Figure 1E), but the level of intracytoplasmic Gal-9 in AML
LSCs was higher than that in normal HSCs (Figure 1F).
IntracytoplasmicGal-9 doesnot necessarilymean its secretion
because Gal-9 lacks a sequence essential for secretion through
ER-Golgi pathway (Hughes, 1999). Prior to secretion, Gal-9 ap-
pears as a translocation intermediate through the lipid bilayer of
cell membrane (Oomizu et al., 2012). Therefore, Gal-9-secreting
cells have Gal-9 on their membrane. To enumerate cells having
membrane Gal-9 without detecting Gal-9 bound to surface
TIM-3, we stained membrane Gal-9 with an antibody (9M1-3),
which specifically recognizes the CRD of Gal-9 that binds the
IgV domain of TIM-3. In TIM-3+ AML patients, a considerable
population of CD34+CD38 LSCs and CD34+CD38+ primitive
blasts had membrane Gal-9, and its expression declined
in CD34 blasts on fluorescence-activated cell sorting (FACS)
analysis (Figures 1G and 1H). In contrast, in a TIM-3 AML
patient, LSCs and primitive blasts did not express membrane
Gal-9 (Figure 1G), and in normal hematopoiesis, HSCs, HPCs,
T cells, monocytes, B cells, and natural killer (NK) cells (data
not shown) did not have membrane Gal-9 at least at the steady
state (Figures 1G and 1H). These results strongly suggest that
TIM-3+ leukemic stem and blast cells actively secrete Gal-9.
To test whether these AML cells secrete an amount of Gal-9
sufficient to cause elevation of serum Gal-9, we measured
Gal-9 concentration in sera from mice reconstituted with human
AML.CD34+ blasts from three AMLpatients, CD34+ lymphoblasts
from two B-ALL patients, and three CD34+ cord blood (CB) were
transplanted into the NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)
(Ishikawa et al., 2005) or the C57BL/6.Rag2nullIl2rgnullNOD-
Sirpa (BRGS) strains (Yamauchi et al., 2013). Two months after
the xenogeneic transplantation, human cell chimerism reached
10.4%, 86.5%, and 69.2% in average in mice reconstituted with
human AML (n = 10), B-ALL (n = 4), and CB (n = 12), respectively.
Strikingly, althoughmice engraftedwith humanAMLcells showed
relatively low human cell chimerisms, sera frommice grafted with
AML contained a very high level of human Gal-9 (220 pg/ml in
average), whereas sera from mice reconstituted with B-ALL or
CB cells contained only <20 pg/ml of Gal-9 (Figure 2A). Based
on these data, we hypothesized that TIM-3 and Gal-9 constitute
a critical autocrine loop to promote maintenance and/or develop-
ment of AML LSCs.
Inhibition of Gal-9 Binding to TIM-3 Inhibited
Reconstitution and Self-Renewal of Human AML LSCs in
a Xenogeneic Transplantation Model
To test whether the putative TIM-3/Gal-9 autocrine signaling
is critical for function of LSCs, we blocked serum Gal-9 to bind
to surface TIM-3 by utilizing a neutralizing Gal-9 antibody
(9M1-3) (Klibi et al., 2009; Sada-Ovalle et al., 2012) in xenogeneic
hosts. Purified CD34+ cells from four AML cases (patients 2,
14, 26, and 28) were transplanted into irradiated NSG mice.nc.
Figure 1. Gal-9, a Ligand for TIM-3, Is Produced from AML LSCs and Primitive AML Cells
(A) Results of the SPR assay by using the Biacore T100 system. Gal-9 but not Gal-1 exhibited a binding phase to human TIM-3-FLAG-Fc protein and then a
dissociation phase, indicating physiological binding of Gal-9 to the extracellular domain of human TIM-3.
(B) WB analysis of human Gal-9 after immunoprecipitation of cells from five cases with human AML (patients 10, 11, 12, 26, and 27 in Table S1) by using an anti-
human TIM-3 antibody. Gal-9 was co-immunoprecipitated with TIM-3 in all five cases tested.
(C) Serum concentration of Gal-9 measured by ELISA in 15 cases of TIM-3+ AML, and in patients with NHL, B-ALL, and healthy controls.
(D) Intracellular FACS analysis of Gal-9 expression of CD34+CD38 AML LSCs (red line) and CD34+CD38+ AML cells (blue line). FMO (fluorescence minus one)
isotype control (black line) was used to define the negative expression. Representative data from eight independent experiments are shown.
(E) Intracellular FACS analysis of Gal-9 in CD34+CD38 HSCs (red line), CD34+CD38+ HPCs (blue line), and CD34 mature cells (yellow line) in normal human
hematopoiesis.
(F) Intracellular FACS analysis of Gal-9 in normal HSCs and LSCs from patient 13.
(G) Representative FACS analysis of membrane Gal-9 protein in TIM-3+ AML (patient 14), TIM-3 AML (patient 35), and normal control.
(H) Summarized data of membrane Gal-9 expression in experiments by using cells from 14 cases with TIM-3+ AML. See also Table S1. Data are represented as
mean ± SEM. *p < 0.05.Forty-eight hours after transplantation, 200 mg of a neutralizing
anti-human Gal-9 antibody or the same dose of control IgG
was intraperitoneally injected once a week for eight times, and
then mice were sacrificed. In all four independent experiments,
mice injected with control IgG efficiently reconstituted human
AML, whereas mice treated with the anti-human Gal-9 antibody
exhibited significant reduction of human AML reconstitution and
CD34+CD38 LSC numbers (Figure 2B). Reconstitution of nor-
mal hematopoiesis from CB was not affected by the antibody
treatment (Figure 2B). These results strongly suggest that
blockage of TIM-3/Gal-9 binding impaired human AML reconsti-
tution through inhibiting self-renewing expansion of LSCs.Cell SIn order to verify this anti-LSC self-renewal effect of Gal-9
neutralization, we re-transplanted 106 hCD34+ AML cells from
primary NSG recipients into secondary NSG recipients, and
8 weeks after the secondary transplantation, we evaluated re-
engraftment of human AML. In both two independent experi-
ments, all six secondary recipients transplanted with bone
marrow (BM) cells from primary recipients treated with control
IgG developed AML, whereas none of six mice transplanted
with cells from anti-Gal-9 antibody treated primary recipients
developed AML (Figure 2C). Thus, anti-Gal-9 antibody treatment
effectively eliminated functional LSCs capable of self-renewal in
primary recipients.tem Cell 17, 341–352, September 3, 2015 ª2015 Elsevier Inc. 343
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Figure 2. An Autocrine Loop Constituted with TIM-3 and Gal-9 Is Necessary for LSCs to Reconstitute and Self-Renew in a Xenograft Model
(A) Serum human Gal-9 concentration in mice reconstituted with CB, B-ALL, and AML (patients 8, 10, and 14). Note that serum human Gal-9 is elevated only in
mice reconstituted with primary AML.
(B) Representative results of Gal-9 neutralization experiments in mice xenografted with human CD34+ AML cells from TIM-3+ AML patients or with normal CB
cells. Injection of an anti-Gal-9 antibody significantly inhibited reconstitution of AML as well as LSCs, but not normal CB reconstitution.
(C) The representative FACS data of secondary NSG recipients transplanted with the residual hCD34+ AML cells purified from primary recipients. Representative
results of two independent experiments using cells from patient 2 are shown.
(D) Sequential analysis of circulating human AML burden in mice reconstituted with TIM-3+ AML (patient 26) after the initiation of Gal-9 neutralization.
(E) Frequencies of hCD45+hCD34+hCD38 LSCs in recipient mice with or without Gal-9 neutralization on day 30. See also Figure S1. Data are represented as
mean ± SEM. *p < 0.05.Anti-Human Gal-9 Antibodies Significantly Reduced the
Leukemic Burden of Human AML, at Least by Targeting
AML LSC Population
We then evaluated whether blocking Gal-9 binding is able to
treat human AML in our xenograft model. CD34+ AML cells
were transplanted into irradiated NSG mice and 8 weeks after
transplantation when successful engraftment of human AML
was confirmed by blood sampling, the injection of 500 mg anti-
humanGal-9 antibody (9M1-3) was started (day 0) and continued
once every 10 days. The change of hCD45+ leukemic burden in
blood was serially evaluated. As shown in Figure 2D, after day
20, human AML cells and CD34+CD38 LSCs were significantly
reduced in mice injected with the anti-Gal-9 antibody, as com-
pared with those injected with control IgG (Figure S1A). Further-
more, on day 30, when mice were sacrificed, the number of
CD34+CD38 LSCs in anti-Gal-9 antibody-treated mice was
significantly lower than that in control mice (Figure 2E). These344 Cell Stem Cell 17, 341–352, September 3, 2015 ª2015 Elsevier Idata strongly suggest that TIM-3 signaling is critical for mainte-
nance of human AML and that reduction of human AML burden
was achieved by directly targeting AML LSCs.
Ligation of TIM-3 by Gal-9 Activates NF-kB and
b-Catenin Pathways in Primitive Human AML Cells
To clarify the function of TIM-3/Gal-9 interaction in primary
AML cells, purified CD34+TIM-3+ AML cells were cultured with
500 pg/ml of Gal-9 for 20 hr and were then subjected to cDNA
microarray analysis. In all three independent experiments using
cells from patients 9, 10, and 29, Gal-9 induced significant
changes in the level of gene expression in CD34+ AML blasts.
To clarify the signaling pathways that are involved in TIM-3/
Gal-9 signaling in AML cells, genes with significant up and
downregulation (>2.5-fold and p < 0.05) by Gal-9 ligation
were subjected to the pathway enrichment analysis based on
the WikiPathways (Kelder et al., 2012) using the Genespringnc.
BD EC
A
Figure 3. Ligation of TIM-3 by Gal-9 Activates the NF-kB Pathway in Primary AML Cells
(A) Tyrosine phosphorylation of TIM-3 was induced in response to 1.0 ng/ml of Gal-9 in TIM-3+ AML cells. Representative data of three TIM-3+ AML patients
tested (patients 10, 26, and 32) are shown.
(B) WB analysis of phosphorylated NF-kB after ligation by 1.0 ng/ml of Gal-9 in primary AML cells. Representative data of TIM-3+ AML cases (patients 2, 3, 10, 12,
and 18) are shown. In contrast, phosphorylation of p65 was not induced in TIM-3 AML cases.
(C) WB analysis of phosphorylated NF-kB, AKT, and ERK after ligation by 5.0 ng/ml of Gal-9 in primary AML cells. Representative data of 4 TIM-3+ AML patients
(patients 2, 3, 12, and 18) are shown.
(D) Phosphorylation of AKT, ERK, and p65 was found in cells from 4 TIM-3+ AML cases (patients 11, 12, 26, and 27) 20 min after ligation of TIM-3 by 5.0 ng/ml of
Gal-9. Representative results in patient 27 are shown. In contrast, Gal-9 could not induce their phosphorylation in cells from a TIM-3 AML patient.
(E) Changes in the amount of phosphorylated ERK and IkBa after ligation by 1.0 ng/ml of Gal-9 in the presence of LY294002, an AKT inhibitor, or U0126, a MEK
inhibitor. Phosphorylation of ERK or IkBa was inhibited by addition of U0126 but not LY294002. See also Figure S2 and Table S2.software (Agilent Technologies). The significantly enriched (p <
0.05) hematopoietic system or cancer-related pathways are
shown in Table S2. Based on these data, we decided to perform
detailed analysis of the NF-kB and the Wnt/b-catenin signaling
induced by TIM-3 ligation because more than a half of these en-
riched pathways used NF-kB signaling (Table S2) and because
the Wnt/b-catenin signaling pathway is frequently involved in
self-renewal of normal and malignant stem cells (Reya et al.,
2003; Wang et al., 2010).
Gal-9 Ligation Induces the Phosphorylation of ERK and
AKT, Resulting in NF-kB Activation in Primitive Human
AML Blasts
It has been shown that ligation of TIM-3 phosphorylates tyrosine
residues of the cytoplasmic tail of TIM-3 and activates Src family
kinases through its cytoplasmic SH2 binding motif at least in
T cells and monocytes (Lee et al., 2011; van de Weyer et al.,
2006). First, the tyrosine phosphorylation of TIM-3 following
Gal-9 stimulation was evaluated in primary AML cells. Purified
CD34+ AML cells were incubated with 1.0 ng/ml of Gal-9, and
TIM-3 was immunoprecipitated from cell membrane extracts
with an anti-TIM-3 antibody and then blotted with either an
anti-phosphotyrosine or anti-TIM-3 antibody. As shown in Fig-Cell Sure 3A, ligation of TIM-3 by Gal-9 induced the phosphorylation
of its cytoplasmic tyrosine residues of TIM-3 in all 3 TIM-3+
AML cases tested. Furthermore, ligation of TIM-3 by 1.0 ng/ml
of Gal-9 also resulted in increased phosphorylation of p65
(RelA) in all five TIM-3+ AML cases tested (Figure 3B). In contrast,
in TIM-3AML cases, Gal-9 did not induce detectable p65 phos-
phorylation in leukemic cells (Figure 3B). Consistent with these
data, significant nucleus translocation of p65 was observed in
CD34+ cells from TIM-3+ AML patients, but not in those from
TIM-3 AML patients (Figure S2).
To identify signaling cascades involved in TIM-3 signaling,
changes of phosphorylation status were tested for multiple
kinases. Ligation of TIM-3 by Gal-9 in primary TIM-3+ AML cells
immediately induced phosphorylation of ERK and AKT, both of
which are upstream of the NF-kB pathway (Richmond, 2002) in
all fourTIM-3+AMLcases tested (Figure3C). Furthermore, to eval-
uate phosphorylation status of single AML cells, we performed a
Phosflow analysis (BD biosciences). Consistent with results of
WB analysis, AKT, ERK1/2 and p65were significantly phosphory-
lated byGal-9 ligation in all four TIM-3+ AML cases tested, but not
in cells from a TIM-3 AML case (Figure 3D). Phosphorylation of
IkBawas inhibited partially by addition of U0126, a MEK inhibitor,
but not by LY294002, an AKT inhibitor in two independenttem Cell 17, 341–352, September 3, 2015 ª2015 Elsevier Inc. 345
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Figure 4. Ligation of TIM-3 by Gal-9 Activates b-Catenin Pathway in Primary AML Cells
(A) Representative results of b-catenin nucleus translocation analysis of primary TIM-3+ AML cells. b-catenin (green) was translocated into the nucleus in
response to Gal-9 (upper). Each dot in bottom panels shows cell size and Nuc-Cyto difference of b-catenin fluorescence intensity of single AML cells. Gal-9
stimulation resulted in significant increment of Nuc-Cyto differences.
(B) Summarized data of Nuc-Cyto differences with or without Gal-9 ligation in 9 TIM-3+ AML cases (patients 2, 3, 10, 13, 16, 17, 26, 29, and 32). The translocation
was not induced in cells from 3 TIM-3 AML patients (patients 33, 34, and 35).
(C) The effect of neutralization of Gal-9 by an anti-Gal-9 monoclonal antibody on nucleus translocation of b-catenin. The promotion of b-catenin translocation
stimulated by exogenous Gal-9 was cancelled by this treatment in all four independent experiments (patients 2, 10, 13, and 26). Representative data are shown.
(D) b-Catenin nucleus translocation induced by Gal-9 ligation or by incubation with IM-12, a GSK3b inhibitor. In all six independent experiments of TIM-3+ AML
cases (patients 2, 3, 10, 13, 26, and 32), the maximum effect of Gal-9 was equal to that of IM-12. Summarized data of six independent experiments are shown.
(E) Induction of b-catenin (Ser552) phosphorylation in TIM-3+ AML (patient 10) by Gal-9 ligation. Data are represented as mean ± SEM. *p < 0.05experiments, indicating that the NF-kB activation by TIM-3
signaling in AML cells is largely dependent on ERK (Figure 3E).
These data strongly suggest that TIM-3 signaling in human AML
involves both ERK and AKT pathways, and in terms of activation
of the NF-kB pathway, the ERK pathway might be critical.
Ligation of TIM-3 by Gal-9 Promotes Nucleus
Translocation of b-catenin in Human CD34+ AML Blasts
Activation of the b-catenin pathway is represented by transloca-
tion of b-catenin from cytoplasm to nuclei. We quantitated
nucleus localization of b-catenin after 20 hr culture of primary
CD34+ AML cells with or without Gal-9. To quantitate its intracel-
lular distribution and their translocation of nucleus in single AML
cells, we digitized the fluorescence intensity of target molecules
in nucleus and cytoplasm of single cells. After a 20-hr culture of
purified CD34+ AML cells with or without Gal-9, the difference be-
tween nucleus and cytoplasm fluorescence intensity (Nuc-Cyto
FI) (Bouck et al., 2011) of b-catenin was measured (Figure S2A).346 Cell Stem Cell 17, 341–352, September 3, 2015 ª2015 Elsevier IThe difference in Nuc-Cyto FI of b-catenin significantly
increased after ligation of TIM-3 by Gal-9 at a concentration of
100 pg/ml to 2 ng/ml in all nine TIM-3+ AML cases tested, but
not in TIM3 AML cases (Figures 4A and 4B). Blocking TIM-3/
Gal-9 interaction by the 9M1-3 antibody abrogated this stimula-
tory effect (Figure 4C). These results indicate that the nucleus
translocation of b-catenin occurs in TIM-3+ AML cells in res-
ponse to the Gal-9 ligation.
GSK3b is a critical inhibitor of the b-catenin pathway by phos-
phorylating b-catenin to be ubiquitinated and dissolved. TIM-3
signaling can activate the ERK and AKT pathways (Figures 3C
and 3D), and both ERK and AKT signaling inhibits GSK3b activity
in cancer, resulting in promotion of nucleus translocation of
b-catenin (Cross et al., 1995; Ding et al., 2005; Yamaguchi
et al., 2012). As shown in Figure 4D, the levels of b-catenin nu-
cleus translocation by addition of Gal-9 were similar to those
induced by IM-12, a GSK3b inhibitor (Schmo¨le et al., 2010) in
all six AML cases tested. Furthermore, consistent with the factnc.
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Figure 5. The TIM-3/Gal-9 Autocrine Loop Exists in Patients with MDS
(A) Progressive increase of TIM-3+ cells within the CD34+CD38 HSC fraction in a RCMD patient who eventually developed overt AML (upper). The CD34+
CD38TIM-3+ population was CD45RA+CD123+, whose phenotype is identical to LSCs in primary AML (bottom).
(B) Percentages of TIM-3+ cells within the CD34+CD38 and CD34+CD38+ fraction of the bone marrow in each type of MDS cases.
(C) Serum Gal-9 levels in each type of MDS cases. Note that even patients with RCMD had a significantly higher level of serum Gal-9 as compared with normal
controls.
(D) Percentages of membrane Gal-9+ cells within the CD34+CD38 HSC and CD34+CD38+ HPC fractions in each type of MDS. Both populations contain sig-
nificant numbers of membrane Gal-9+ cells, suggesting that these populations are responsible for secretion of Gal-9.
(E) Nuc-Cyto difference of b-catenin fluorescence intensity of cells from patients with overt AML after ligation with Gal-9 or after incubation with IM-12, a GSK3b
inhibitor.
(F) Increases in levels of phosphorylated NF-kB (upper) and phosphorylated b-catenin (bottom) after Gal-9 ligation. Representative data in a patient developed
overt AML are shown. Data are represented as mean ± SEM. *p < 0.05.that activated AKT stabilizes b-catenin via phosphorylation of
b-catenin at the site of Ser552 (Fang et al., 2007), continuous
phosphorylation of this site of b-catenin was seen from 20 min
to 20 hr after ligation of TIM-3 by Gal-9 (Figure 4E). These re-
sults suggest that in human AML, TIM-3 signaling activates the
b-catenin pathway via AKT and ERK, in addition to the NF-kB
pathway via ERK.
The TIM-3/Gal-9 Autocrine Loop Is Used in Myeloid
Leukemia Transformed from a Variety of Preleukemic
Disorders
Because the NF-kB and b-catenin pathways are frequently
involved in a variety of cancers (Reya and Clevers, 2005), we
wished to test whether the TIM-3/Gal-9 signaling is used in
leukemic transformation in other myeloid malignancies.
Figure 5A shows chronological FACS analyses in a patient
with primary MDS of the refractory cytopenia with multilineageCell Sdisplasia (RCMD) at diagnosis, who eventually developed
overt AML. In this patient, the expression of TIM-3 within the
CD34+CD38HSC fractionwas slightly but significantly elevated
at the RCMD stage. TIM-3+ HSCs progressively outgrew TIM-3
HSCs, as the disease advanced into the refractory anemia with
excess of blasts (RAEB) 1, RAEB2, and then overt AML, when
virtually all CD34+CD38 LSCs became TIM-3+. As shown in
Figure 5A (bottom), such expanding CD34+CD38TIM-3+ cells
progressively upregulate CD45RA and CD123, becoming analo-
gous to normal GMPs, as LSCs in primary AML do (Yoshimoto
et al., 2009). Figure 5B summarized percentages of TIM-3+ cells
in the CD34+CD38 and CD34+CD38+ fraction in 24 MDS
patients. The percentages of TIM-3+ cells significantly increased
already in RCMD patients and further increased in RAEB
and overt AML patients. Serum Gal-9 elevated significantly,
reaching >300 pg/ml in average early at the RCMD stage (Fig-
ure 5C). Percentages of membrane Gal-9 expressing cellstem Cell 17, 341–352, September 3, 2015 ª2015 Elsevier Inc. 347
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Figure 6. The TIM-3/Gal-9 Autocrine Loop Exists in Patients with MPN
(A) Progressive increase of TIM-3+ cells within the CD34+CD38 HSC fraction at each stage of human CML.
(B) Percentages of TIM-3+ cells within the CD34+CD38 fraction of the bone marrow in CML patients at CP or AP/BC phase.
(C) Percentages of membrane Gal-9+ cells within the CD34+CD38 HSC and the CD34+CD38+ HPC fractions in each clinical phase of CML. Both populations
contain significant numbers of membrane Gal-9+ cells even at the CP.
(D) SerumGal-9 levels in CML patients at the CP or the AP/BC phase. Note that patients at the CP showed a significantly higher level of serumGal-9 as compared
with normal controls.
(E) Gal-9 ligation induced significant nucleus translocation of b-catenin in CD34+ cells from a patient with CML-BC.
(F) Progressive increase of TIM-3+ cells within the CD34+CD38 HSC fraction in a patient with ET (upper) and with CMML (bottom).
(G) Percentages of TIM-3+ cells within the CD34+CD38 fraction of the bonemarrow in theseMPNpatients at diagnosis or when they transformed into overt AML.
(H) Percentages of membrane Gal-9+ cells within the CD34+CD38HSC and the CD34+CD38+ HPC fractions in ET and CMML patients at diagnosis or when they
transformed into overt AML. Both populations contain significant numbers of membrane Gal-9+ cells even at diagnosis.
(I) Serum Gal-9 levels in MPN patients at diagnosis or when they transformed into overt AML.
(J) Gal-9 ligation induced significant nucleus translocation of b-catenin in cells from a patient with CMML. See also Figure S3. Data are represented as
mean ± SEM. Dx, diagnosis. *p < 0.05.were also elevated in both CD34+CD38 and CD34+CD38+ frac-
tions in every stage of MDS (Figure 5D).
Ligation of CD34+TIM-3+ MDS-derived overt AML cells with
Gal-9 induced significant elevation of Nuc-Cyto FI of b-catenin
in all three cases tested, whose levels were similar to those
induced by IM-12, a GSK3b inhibitor (Figure 5E). Ligation by
Gal-9 also induced phosphorylation of NF-kB and b-catenin (Fig-
ure 5F) in CD34+TIM-3+ overt AML cells, as in primary AML cells
did. These data strongly suggest that the TIM-3/Gal-9 autocrine
signaling plays a critical role in disease progression of MDS into
overt AML.
Similarly, at the chronic phase (CP) of CML patients, the
CD34+CD38 HSC fraction contained 20% of TIM-3+ cells,
and the percentage of TIM-3+ cells within the CD34+CD38 frac-
tion progressively increased, as disease stages advanced into348 Cell Stem Cell 17, 341–352, September 3, 2015 ª2015 Elsevier Ithe accelerated phase (AP) and then the blast crisis (BC),
when >80% of CD34+CD38 LSCs became positive for TIM-3
(Figures 6A and 6B). Significantly high proportions of CD34+
CD38 and CD34+CD38+ populations had membrane Gal-9 in
CML patients at every clinical stage (Figure 6C). Serum Gal-9
was also elevated up to 400 pg/ml at the CP phase and
600 pg/ml in the AP/BC phases (Figure 6D). Again, CD34+
CML cells at the CP and AP/BC phases incubated with Gal-9
showed increased phosphorylation level of p65, AKT, and ERK
(Figures S3A and S3B). Significant nucleus translocation of
b-catenin protein was also induced in CD34+ CML cells after
Gal-9 stimulation (Figure 6E).
We also checked the expression of TIM-3 in acute leukemia
transformation from other MPN, including nine patients with
chronicmyelomonocytic leukemia (CMML) and six with essentialnc.
Figure 7. Schema of AML Development
Driven by Self-Renewal Signaling of the
TIM-3/Gal-9 Autocrine Loopthrombocythemia (ET). Interestingly, even in these MPN patients
at their CP, a small fraction of CD34+CD38 HSCs significantly
expressed TIM-3, irrespective of primary diagnosis (Figures 6F
and 6G). These MPN patients had increased numbers of
CD34+ cells expressing membrane Gal-9 (Figure 6H) and
elevated serum Gal-9 up to 400 pg/ml (Figure 6I). After transfor-
mation into overt AML, the vast majority of CD34+CD38 cells
became positive for TIM-3, irrespective of their primary diag-
nosis (Figures 6F and 6G). These cells expressed membrane
Gal-9 (Figure 6H), and patients’ sera contained high levels
of Gal-9 (Figure 6I). TIM-3/Gal-9 interaction again activated
NF-kB and b-catenin signaling in CD34+ MPN cells (Figures 6J,
S3C, and S3D). Thus, the TIM-3/Gal-9 autocrine signaling ap-
pears to be commonly used during development of AML from
most types of preleukemic stages in human.
DISCUSSION
Recent genome analysis of myeloid leukemia has shown that
sequential acquisition of multiple genetic abnormalities is the
principal mechanism for evolution of malignant stem cells to
achieve dominant clonal selection (Walter et al., 2012; Welch
et al., 2012). These genetic abnormalities progressively accumu-
late in self-renewing HSCs, and as a consequence of combina-
tion of critical driver mutations, these genetically impaired, ‘‘pre-
leukemic’’ HSCs can fully transform into LSCs (Jan et al., 2012;
Shlush et al., 2014). During this process, it should be necessary
for preleukemic HSCs to outgrow normal HSCs, and finally, they
self-renew at a HPC stage such as the GMP to become myeloid
LSCs (Krivtsov et al., 2006; Reya et al., 2001; Rossi et al., 2008;
Wang et al., 2005). We here propose the TIM-3/Gal-9 autocrine
loop as a critical mechanism for such clonal dominancy and
self-renewal of LSCs (Figure 7).
We showed evidence that the TIM-3/Gal-9 autocrine loop ac-
tivates both the NF-kB and the b-catenin signaling in most
myeloid leukemias. TIM-3 was originally identified as a protein
expressed specifically in LSCs and primitive blasts in human
AML but not in normal HSCs (Kikushige et al., 2010). Our study
shows that the significant upregulation of TIM-3 in HSC and
HPC populations, as well as elevation of serum Gal-9, occurs
already in patients with preleukemic myeloid disorders, such
as the RCMD stage in MDS, CP, of MPN, including CML. These
data suggest that the acquisition of Gal-9 secretion might be
one of the early events of leukemia progression. In TIM-3+Cell Stem Cell 17, 341–352, SAML patients, Gal-9 is mainly produced
by the CD34+ fraction of AML cells that
contains LSCs and primitive blasts (Fig-
ure 1H). In leukemia transformed from
MDS and MPN, Gal-9 was also secreted
mainly from CD34+ primitive blast popu-
lations (Figures 5D, 6C, 6H, and S3E).
Percentages of TIM-3+ and membrane
Gal-9+ cells progressively increased, aseach disease advanced into secondary overt AML (Figures 5
and 6). The ligation of TIM-3 by Gal-9 at concentrations equiva-
lent to patients’ serum levels induced simultaneous activation of
the NF-kB and b-catenin signaling in leukemia transformed from
MDS and MPN (Figures 5, 6, and S3), as well as in de novo AML.
These data suggest that the TIM-3/Gal-9 autocrine pathway
contributes toward expansion and transformation of malignant
myeloid clones.
Since the serumGal-9 level and percentage ofmembrane Gal-
9+ cells were upregulated already at early stages of MDS orMPN
patients, it is possible that the upregulation of Gal-9 level is
an early event prior to the increase of TIM-3 in leukemia cells.
It should be critical to elucidate the molecular mechanism of
Gal-9 upregulation in future studies. An exome sequence anal-
ysis of TIM-3+ and TIM-3 fractions in AML patients has shown
that the TIM-3+CD34+CD38 LSC population represents highly
mutated ‘‘late’’ clones, whereas the TIM-3CD34+CD38 popu-
lation consists of less mutated preleukemic HSCs (Jan et al.,
2011, 2012). In our analysis, Gal-9 itself did not stimulate the
expression of TIM-3 in AML cells at least in vitro (data not
shown). These results support our hypothesis that the TIM-3/
Gal-9 autocrine signaling plays a critical role in clonal selection,
in which preleukemic HSCs progressively outgrow normal HSCs
(Figure 7). After leukemic transformation, this pathway becomes
essential for LSCs to exert their stem cell function in AML
because neutralization of serum human Gal-9 in xenogeneic
hosts significantly blocked reconstitution and self-renewal of hu-
man AML LSCs (Figure 2). TIM-3/Gal-9 signaling may also be
critical for survival of LSCs because we found that deprivation
of Gal-9 accelerated apoptotic cell death of LSCs at least
in vitro (Figure S1B). Our proposal for scheme of AML progres-
sion from HSCs, driven by the TIM-3 and Gal-9 autocrine ma-
chinery, is schematized in Figure 7.
Previous studies have proposed that AML cells should be
able to stimulate themselves to expand and survive because
myeloid leukemic cells can produce cytokines or growth factors,
including GM-CSF (Akashi et al., 1991), G-CSF (Murohashi et al.,
1989), IL-1b (Oster et al., 1989), IL-6 (Gallipoli blood 2013), and
TNF-a (Oster et al., 1989). In fact, cytokine signaling is known
to activate NF-kB, and NF-kB signaling is constitutively active
in AML LSCs but not in normal HSCs (Guzman et al., 2001).
Although such autocrine signaling has been shown to exist in
some human leukemias (Akashi et al., 1991), this hypothesis
may not be accepted as a fundamental mechanism for growtheptember 3, 2015 ª2015 Elsevier Inc. 349
or self-renewal of LSCs in AML. For example, a recent report
showed that activation of NF-kB pathway in AML occurs inde-
pendent of autocrine production of cytokines or their receptor
mutations such as FLT-3, but it is dependent on activation of
Ras pathway (Birkenkamp et al., 2004). In our data, ligation of
TIM-3 by Gal-9 in CD34+ AML cells can induce phosphorylation
of NF-kB, and consistent with the report, this NF-kB activation
occurs via ERK, a signaling molecule downstream of Ras (Fig-
ure 3E). Thus, the TIM-3/Gal-9 autocrine loop might be at least
one of the critical mechanisms for NF-kB activation in myeloid
leukemias.
b-catenin is a key molecule in self-renewing machinery of both
normal and malignant HSCs (Reya et al., 2003; Wang et al.,
2010). In a mouse AML model, activation of b-catenin pathway
is necessary for LSCs to gain self-renewal activity, when mouse
non-self-renewing GMP cells were transformed into AML LSCs
by retrovirally enforced MLL-AF9 expression (Wang et al.,
2010). Primary AML cells constitutively activated this pathway
(Simon et al., 2005), and high expression of b-catenin protein
in AML cells predicts enhanced colony formation and poor prog-
nosis (Ysebaert et al., 2006). Furthermore, in human CML, accu-
mulation of b-catenin to the nucleus occurs especially in the
CD45RA+CD123+ population of GMP-like phenotype that is
finally transformed into LSCs at myeloid BC (Jamieson et al.,
2004). Our data show that nucleus translocation of b-catenin
occurs in response to Gal-9 in CD34+CD38CD45RA+CD123+
LSCs not only from primary AML, but also from overt myeloid
leukemia progressed from MDS and MPN, including CML. Liga-
tion of TIM-3 by Gal-9 induces phosphorylation of ERK and AKT,
whose signaling can inhibit GSK3b, a molecule responsible for
degradation of b-catenin by ubiquitination (Yamaguchi et al.,
2012). Ligation of TIM-3 also phosphorylates Ser552 of b-catenin
for stabilization. Accordingly, TIM-3/Gal-9 signaling might acti-
vate the b-catenin pathway via both ERK and AKT in human
myeloid leukemias.
The co-activation of NF-kB and b-catenin pathways has been
reported to play a cooperative role in conferring cancer-stem-
cell properties to non-stem cells in an intestinal cancer model
(Schwitalla et al., 2013). In this case, phosphorylated NF-kB
binds to b-catenin via CREB-binding protein to strengthen b-cat-
enin transcriptional activities, resulting in generation of strong
self-renewal signaling. These data collectively suggest that the
TIM-3/Gal-9 autocrine signaling activates both NF-kB and b-cat-
enin pathways to outcompete normal HSCs by promoting self-
renewal of LSCs in most types of human myeloid leukemia.
Thus, our data suggest that TIM-3 and Gal-9 constitute a
pan-myeloid autocrine loop to develop malignant stem cells in
human myeloid malignancies. Signaling molecules downstream
of TIM-3 and Gal-9 ligation, as well as surface TIM-3 itself, might
be good candidates for cancer stem cell-target therapy common
to humanmyeloidmalignancies. Such therapies should be useful
not only to eradicate LSCs in AMLs, but also to prevent progres-
sion into overt AML in most preleukemic myeloid disorders.EXPERIMENTAL PROCEDURES
Clinical Samples
The BM, peripheral blood (PB), and serum samples of adult hematological ma-
lignancies diagnosed according to World Health Organization (WHO) criteria350 Cell Stem Cell 17, 341–352, September 3, 2015 ª2015 Elsevier Iwere enrolled in this study. Table S1 summarizes the primary AML patients’
characteristics analyzed in this study. Human adult BM and PB samples
were obtained from healthy donors or purchased from AllCells. CB cells
were obtained from full-term deliveries (provided by the Kyushu Block Red
Cross Blood Center, Japan Red Cross Society). Informed consent was ob-
tained from all patients and controls in accordance with the Helsinki Declara-
tion of 1975 that was revised in 1983. The Institutional Review Board of Kyushu
University Hospital approved all research on human subjects.
Purification of AML LSCs and Normal HSCs
For the analyses and sorting of humanHSCs and HPCs, cells were stained and
sorted by FACS Aria, Aria2, and Aria3 (BD Biosciences). Detailed experimental
procedures and antibodies used in the FACS analysis are described in the
Supplemental Experimental Procedures.
Surface Plasmon Resonance Assay
The binding of Gal-9 to TIM-3 was analyzed using Biacore T100 system (GE
Healthcare). Detailed experimental procedures are described in the Supple-
mental Experimental Procedures.
Measurement of Serum Gal-9 Concentration
Serum human Gal-9 was measured by using a Human Galectin-9 ELISA kit
(KAMIYA Biomedical Company) according to the manufacturer’s instructions.
We scanned the precoated 96-well plates provided by Multiskan FC (Thermo
Fisher Scientific) at a wavelength of 450 nm.
Quantitation for Nucleus Translocation of b-Catenin and p65
Detailed experimental procedures are described in the Supplemental Experi-
mental Procedures.
Xenogeneic Transplantation into Immunodeficient Mice
NSG mice (Ishikawa et al., 2005; Shultz et al., 2005) were purchased from
Charles River Laboratories Japan. BRGS mice were developed in our labora-
tory (Yamauchi et al., 2013). Both mice were bred and housed at Kyushu Uni-
versity. Animal experiments were performed according to the institutional
guidelines approved by the animal care committee of Kyushu University.
Detailed experimental procedures are described in the Supplemental Experi-
mental Procedures.
Microarray Analysis, Immunoprecipitation, and Western Blot
Analysis
Detailed experimental procedures are described in the Supplemental Experi-
mental Procedures.
Statistical Analysis
Data are represented asmean ± SEM. The significance of differences between
two groups was determined by Student’s t test. p values < 0.05 were consid-
ered statistically significant. False discovery rate (FDR)-adjusted p values
(q values) were calculated with two-stage sharpened method (Benjamini
et al., 2006).
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